160 related articles for article (PubMed ID: 36982943)
21. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
22. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Hallberg P; Lind L; Billberger K; Michaelsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
Clin Cardiol; 2004 Mar; 27(3):169-73. PubMed ID: 15049387
[TBL] [Abstract][Full Text] [Related]
24. Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer-indications for anti-TNF-α agents in cancer treatment.
Grimm M; Lazariotou M; Kircher S; Höfelmayr A; Germer CT; von Rahden BH; Waaga-Gasser AM; Gasser M
Cell Oncol (Dordr); 2011 Aug; 34(4):315-26. PubMed ID: 21573932
[TBL] [Abstract][Full Text] [Related]
25. Mutations in the notch signalling pathway are associated with enhanced anti-tumour immunity in colorectal cancer.
Wang F; Long J; Li L; Zhao ZB; Wei F; Yao Y; Qiu WJ; Wu ZX; Luo QQ; Liu W; Quan YB; Lian ZX; Cao J
J Cell Mol Med; 2020 Oct; 24(20):12176-12187. PubMed ID: 32924269
[TBL] [Abstract][Full Text] [Related]
26. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
27. Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer.
Grimm M; Kim M; Rosenwald A; von Raden BH; Tsaur I; Meier E; Heemann U; Germer CT; Gasser M; Waaga-Gasser AM
Eur J Cancer; 2010 Aug; 46(12):2314-23. PubMed ID: 20580220
[TBL] [Abstract][Full Text] [Related]
28. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
29. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
30. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
31. The Interplay Between Neutrophils and CD8
Governa V; Trella E; Mele V; Tornillo L; Amicarella F; Cremonesi E; Muraro MG; Xu H; Droeser R; Däster SR; Bolli M; Rosso R; Oertli D; Eppenberger-Castori S; Terracciano LM; Iezzi G; Spagnoli GC
Clin Cancer Res; 2017 Jul; 23(14):3847-3858. PubMed ID: 28108544
[No Abstract] [Full Text] [Related]
32. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
[TBL] [Abstract][Full Text] [Related]
33. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Kurland L; Liljedahl U; Karlsson J; Kahan T; Malmqvist K; Melhus H; Syvänen AC; Lind L
Am J Hypertens; 2004 Jan; 17(1):8-13. PubMed ID: 14700505
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman KP; Nyström F; Hägg A; Lind L;
J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
[TBL] [Abstract][Full Text] [Related]
36. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory effects of renin-angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases.
Vallejo Ardila DL; Walsh KA; Fifis T; Paolini R; Kastrappis G; Christophi C; Perini MV
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448803
[TBL] [Abstract][Full Text] [Related]
38. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
[TBL] [Abstract][Full Text] [Related]
40. Irbesartan (a comprehensive profile).
Darwish IA; Darwish HW; Bakheit AH; Al-Kahtani HM; Alanazi Z
Profiles Drug Subst Excip Relat Methodol; 2021; 46():185-272. PubMed ID: 33461698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
